The stock of Moderna Inc (NASDAQ:MRNA) last traded at $42.58, down -3.80% from the previous session.
MRNA stock price is now -18.05% away from the 50-day moving average and -55.07% away from the 200-day moving average. The market capitalization of the company currently stands at $16.39B.
With the price target of $42, Berenberg recently initiated with Hold rating for Moderna Inc (NASDAQ: MRNA). On November 18, 2024, HSBC Securities Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $58, while ‘Wolfe Research’ rates the stock as ‘Underperform’
In other news, Klinger Shannon Thyme, Officer bought 112 shares of the company’s stock on Dec 03 ’24. The stock was bought for $4,849 at an average price of $43.30. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 03 ’24, Officer Hoge Stephen bought 314 shares of the business’s stock. A total of $13,595 was incurred on buying the stock at an average price of $43.30.
During the past 12 months, Moderna Inc has had a low of $35.80 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.39, and a quick ratio of 4.20. The fifty day moving average price for MRNA is $52.3912 and a two-hundred day moving average price translates $94.994774 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-09-30. The net profit margin was -43.84% and return on equity was -17.52% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $1.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.69 percent.
